AbbVie's Allergan division has launched Boey, a botulinum toxin formulation designed for rapid onset, and has secured EU regulatory approval. The product targets the competitive gap where practitioners and patients seek faster results—traditionally a weakness of toxin injectables, which typically require 3–7 days for full effect.
Injectables
AbbVie Launches Boey, Rapid-Onset Botulinum Toxin, With EU Approval
New formulation claims faster onset than Botox; FDA pathway in U.S. unclear.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
AbbVie's Boey claims faster onset than traditional Botox; EU approved, U.S. pathway unclear.
Boey's mechanism and potency relative to Botox remain proprietary, but the rapid-onset claim, if clinically validated, could reshape toxin prescribing patterns. AbbVie has not disclosed a U.S. FDA pathway or timeline. For practice owners, the strategic question is whether Boey will command a premium price or be positioned as a value alternative. Either way, it signals that the toxin category—long considered mature—is still innovating, and that differentiation on onset speed is now table stakes.
Source: original report ↗
Frequently asked questions
What is Boey and how is it different from Botox?
Boey is a new botulinum toxin formulation launched by AbbVie's Allergan division that claims faster onset than traditional Botox. While the exact mechanism and potency remain proprietary, Boey is designed to deliver results in less time than the standard 3–7 days required for conventional toxin injectables.
How quickly does Boey work compared to regular Botox?
AbbVie claims Boey has rapid onset, addressing the traditional weakness of botulinum toxins that typically require 3–7 days for full effect. However, specific onset timelines have not been disclosed in available materials.
Is Boey approved in the United States?
Boey has secured EU regulatory approval, but AbbVie has not disclosed a U.S. FDA pathway or timeline for approval. The product is currently available in European markets only.
Will Boey be more expensive than Botox?
AbbVie has not announced pricing for Boey. The strategic positioning—whether as a premium product or value alternative—remains unclear and will likely depend on clinical validation and competitive market dynamics.
What does Boey's launch mean for medspa practices?
Boey signals that the mature toxin category is still innovating and that onset speed is becoming a key differentiator in patient expectations. Practice owners should monitor its U.S. approval status and pricing strategy to assess competitive impact.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.